Dystrophinopathies and Limb-Girdle Muscular Dystrophies

Joana Domingos; Anna Sarkozy; Mariacristina Scoto; Francesco Muntoni

doi:10.1055/s-0037-1601860

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2017; 48(04): 262-272
DOI: 10.1055/s-0037-1601860

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Dystrophinopathies and Limb-Girdle Muscular Dystrophies

Authors

Joana Domingos

¹UCL Great Ormond Street Institute of Child Health, Department of Molecular Neurosciences, Dubowitz Neuromuscular Centre and Great Ormond Street Hospital, London, United Kingdom
Anna Sarkozy

¹UCL Great Ormond Street Institute of Child Health, Department of Molecular Neurosciences, Dubowitz Neuromuscular Centre and Great Ormond Street Hospital, London, United Kingdom
Mariacristina Scoto

¹UCL Great Ormond Street Institute of Child Health, Department of Molecular Neurosciences, Dubowitz Neuromuscular Centre and Great Ormond Street Hospital, London, United Kingdom
Francesco Muntoni

¹UCL Great Ormond Street Institute of Child Health, Department of Molecular Neurosciences, Dubowitz Neuromuscular Centre and Great Ormond Street Hospital, London, United Kingdom

Abstract

Muscular dystrophies are a heterogeneous group of inherited diseases. The natural history of these disorders along with their management have changed mainly due to a better understanding of their pathophysiology, the evolution of standards of care, and new treatment options. Dystrophinopathies include both Duchenne's and Becker's muscular dystrophies, but in reality they are a spectrum of muscle diseases caused by mutations in the gene that encodes the protein dystrophin. Duchenne's muscular dystrophy is the most common form of inherited muscle disease of childhood. The current standards of care considerably prolong independent ambulation and survival. Several therapeutic options either aiming at substituting/correcting the primary protein defect or limiting the progression of the dystrophic process are currently being explored in clinical trials.

Limb-girdle muscular dystrophies (LGMDs) are rare and heterogeneous conditions, characterized by weakness and wasting of the pelvic and shoulder girdle muscles. Originally classified into dominant and recessive, > 30 genetic forms of LGMDs are currently recognized. Further understanding of the pathogenic mechanisms of LGMD will help identifying novel therapeutic approaches that can be tested in clinical trials.

Keywords

muscular dystrophy - limb-girdle muscular dystrophy - dystrophinopathies - Duchenne's muscular dystrophy - Becker's muscular dystrophy

Volltext

Referenzen

References
1 Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2 (12) 731-740
2 Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol 1997; 12 (03) 329-343
3 Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2014; 24 (06) 482-491
4 Siciliano G, Tessa A, Renna M, Manca ML, Mancuso M, Murri L. Epidemiology of dystrophinopathies in North-West Tuscany: a molecular genetics-based revisitation. Clin Genet 1999; 56 (01) 51-58
5 Talkop UA, Kahre T, Napa A. , et al. A descriptive epidemiological study of Duchenne muscular dystrophy in childhood in Estonia. Eur J Paediatr Neurol 2003; 7 (05) 221-226
6 Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977–2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord 2003; 13 (10) 804-812
7 Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 2013; 21 (10) 1049-1053
8 Greenberg CR, Rohringer M, Jacobs HK. , et al. Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. Lancet 1988; 2 (8608): 425-427
9 Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1991; 1 (01) 19-29
10 Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50 (03) 509-517
11 Kenwrick S, Patterson M, Speer A, Fischbeck K, Davies K. Molecular analysis of the Duchenne muscular dystrophy region using pulsed field gel electrophoresis. Cell 1987; 48 (02) 351-357
12 Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet 1993; 3 (04) 283-291
13 Bladen CL, Salgado D, Monges S. , et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 2015; 36 (04) 395-402
14 Mercuri E, Muntoni F. Muscular dystrophies. Lancet 2013; 381 (9869): 845-860
15 Rosenberg AS, Puig M, Nagaraju K. , et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med 2015; 7 (299) 299rv4
16 Serrano AL, Muñoz-Cánoves P. Fibrosis development in early-onset muscular dystrophies: mechanisms and translational implications. Semin Cell Dev Biol 2016; S1084-9521 (16) 30304-4
17 Vallejo-Illarramendi A, Toral-Ojeda I, Aldanondo G, López de Munain A. Dysregulation of calcium homeostasis in muscular dystrophies. Expert Rev Mol Med 2014; 16: e16
18 Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genomics Hum Genet 2015; 16: 281-308
19 Sander M, Chavoshan B, Harris SA. , et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000; 97 (25) 13818-13823
20 Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin 2014; 32 (03) 671-688 , viii
21 Brandsema JF, Darras BT. Dystrophinopathies. Semin Neurol 2015; 35 (04) 369-384
22 Iyadurai SJ, Kissel JT. The Limb-Girdle muscular dystrophies and the dystrophinopathies. Continuum (Minneap Minn) 2016; 22 (6, Muscle and Neuromuscular Junction Disorders): 1954-1977
23 Scott E, Eagle M, Mayhew A. , et al; North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012; 17 (02) 101-109
24 Mayhew A, Mazzone ES, Eagle M. , et al; Performance of the Upper Limb Working Group. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 2013; 55 (11) 1038-1045
25 Kamdar F, Garry DJ. Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 2016; 67 (21) 2533-2546
26 van Westering TL, Betts CA, Wood MJ. Current understanding of molecular pathology and treatment of cardiomyopathy in Duchenne muscular dystrophy. Molecules 2015; 20 (05) 8823-8855
27 Mavrogeni S, Markousis-Mavrogenis G, Papavasiliou A, Kolovou G. Cardiac involvement in Duchenne and Becker muscular dystrophy. World J Cardiol 2015; 7 (07) 410-414
28 Melacini P, Fanin M, Danieli GA. , et al. Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. Circulation 1996; 94 (12) 3168-3175
29 LoMauro A, D'Angelo MG, Aliverti A. Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. Ther Clin Risk Manag 2015; 11: 1475-1488
30 Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 2001; 164 (12) 2191-2194
31 Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ. Duchenne muscular dystrophy: the management of scoliosis. J Spine Surg 2016; 2 (03) 185-194
32 Snow WM, Anderson JE, Jakobson LS. Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review. Neurosci Biobehav Rev 2013; 37 (05) 743-752
33 Schade van Westrum SM, Hoogerwaard EM, Dekker L. , et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. Neurology 2011; 77 (01) 62-66
34 Viggiano E, Ergoli M, Picillo E, Politano L. Determining the role of skewed X-chromosome inactivation in developing muscle symptoms in carriers of Duchenne muscular dystrophy. Hum Genet 2016; 135 (07) 685-698
35 Ferlini A, Flanigan KM, Lochmuller H, Muntoni F, tHoen PA, McNally E. 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24–26 January 2014, Naarden, The Netherlands. Neuromuscul Disord 2015; 25 (02) 184-198
36 Bello L, Piva L, Barp A. , et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 2012; 79 (02) 159-162
37 Pegoraro E, Hoffman EP, Piva L. , et al; Cooperative International Neuromuscular Research Group. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76 (03) 219-226
38 Bello L, Kesari A, Gordish-Dressman H. , et al; Cooperative International Neuromuscular Research Group Investigators. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann Neurol 2015; 77 (04) 684-696
39 Flanigan KM, Ceco E, Lamar KM. , et al; United Dystrophinopathy Project. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol 2013; 73 (04) 481-488
40 Vo AH, McNally EM. Modifier genes and their effect on Duchenne muscular dystrophy. Curr Opin Neurol 2015; 28 (05) 528-534
41 Bello L, Flanigan KM, Weiss RB. , et al; United Dystrophinopathy Project; Cooperative International Neuromuscular Research Group. Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. Am J Hum Genet 2016; 99 (05) 1163-1171
42 Cacchiarelli D, Legnini I, Martone J. , et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011; 3 (05) 258-265
43 Zaharieva IT, Calissano M, Scoto M. , et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. PLoS One 2013; 8 (11) e80263
44 Roberts TC, Blomberg KE, McClorey G. , et al. Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids 2012; 1: e39
45 Perry MM, Muntoni F. Noncoding RNAs and Duchenne muscular dystrophy. Epigenomics 2016; 8 (11) 1527-1537
46 Nadarajah VD, van Putten M, Chaouch A. , et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011; 21 (08) 569-578
47 Hathout Y, Seol H, Han MH, Zhang A, Brown KJ, Hoffman EP. Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics 2016; 13: 9
48 Marden FA, Connolly AM, Siegel MJ, Rubin DA. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005; 34 (03) 140-148
49 Forbes SC, Walter GA, Rooney WD. , et al. Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology 2013; 269 (01) 198-207
50 Kim HK, Laor T, Horn PS, Wong B. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment. Korean J Radiol 2010; 11 (03) 304-311
51 Kim HK, Serai S, Lindquist D. , et al. Quantitative skeletal muscle MRI: part 2, MR spectroscopy and T2 relaxation time mapping—comparison between boys with Duchenne muscular dystrophy and healthy boys. AJR Am J Roentgenol 2015; 205 (02) W216-23
52 Johnston JH, Kim HK, Merrow AC. , et al. Quantitative skeletal muscle MRI: part 1, derived T2 fat map in differentiation between boys with Duchenne muscular dystrophy and healthy boys. AJR Am J Roentgenol 2015; 205 (02) W207-15
53 Ponrartana S, Ramos-Platt L, Wren TA. , et al. Effectiveness of diffusion tensor imaging in assessing disease severity in Duchenne muscular dystrophy: preliminary study. Pediatr Radiol 2015; 45 (04) 582-589
54 Hooijmans MT, Damon BM, Froeling M. , et al. Evaluation of skeletal muscle DTI in patients with Duchenne muscular dystrophy. NMR Biomed 2015; 28 (11) 1589-1597
55 Ricotti V, Evans MR, Sinclair CD. , et al. Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials. PLoS One 2016; 11 (09) e0162542
56 Willcocks RJ, Triplett WT, Forbes SC. , et al. Magnetic resonance imaging of the proximal upper extremity musculature in boys with Duchenne muscular dystrophy. J Neurol 2017; 264 (01) 64-71
57 Ricotti V, Jägle H, Theodorou M, Moore AT, Muntoni F, Thompson DA. Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system. Eur J Hum Genet 2016; 24 (04) 562-568
58 Aartsma-Rus A. Dystrophin analysis in clinical trials. J Neuromuscul Dis 2014; 1 (01) 41-53
59 Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 2016; 53 (03) 145-151
60 Bushby K, Finkel R, Birnkrant DJ. , et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9 (01) 77-93
61 Gatheridge MA, Kwon JM, Mendell JM. , et al. Identifying non-Duchenne muscular dystrophy-positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review. JAMA Neurol 2016; 73 (01) 111-116
62 Bushby K, Finkel R, Birnkrant DJ. , et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9 (02) 177-189
63 Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol 1993; 240 (02) 98-104
64 Yazaki M, Yoshida K, Nakamura A. , et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999; 42 (03) 145-149
65 Straub V, Balabanov P, Bushby K. , et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol 2016; 15 (08) 882-890
66 FDA approves drug to treat Duchenne muscular dystrophy [press release]. February 7, 2017
67 Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 2016; (05) CD003725
68 Ricotti V, Ridout DA, Scott E. , et al; NorthStar Clinical Network. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84 (06) 698-705
69 Excellence N-NIfHaC. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. . In: Excellence N-NIfHaC, ed. 2016
70 FDA grants accelerated approval to first drug for Duchenne muscular dystrophy [press release]. 2016
71 Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res 2016; 8 (06) 2471-2489
72 Robinson-Hamm JN, Gersbach CA. Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy. Hum Genet 2016; 135 (09) 1029-1040
73 Mah JK. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat 2016; 12: 1795-1807
74 Buyse GM, Voit T, Schara U. , et al; DELOS Study Group. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 2015; 385 (9979): 1748-1757
75 Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132 (Pt 11): 3175-3186
76 van der Kooi AJ, Barth PG, Busch HF. , et al. The clinical spectrum of limb girdle muscular dystrophy. A survey in the Netherlands. Brain 1996; 119 (Pt 5): 1471-1480
77 Urtasun M, Sáenz A, Roudaut C. , et al. Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain 1998; 121 (Pt 9): 1735-1747
78 Magri F, Nigro V, Angelini C. , et al. The Italian limb girdle muscular dystrophy registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve 2017; 55 (01) 55-68
79 Penttilä S, Palmio J, Suominen T. , et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012; 78 (12) 897-903
80 Hicks D, Sarkozy A, Muelas N. , et al. A founder mutation in anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011; 134 (Pt 1): 171-182
81 Brun BN, Mockler SR, Laubscher KM. , et al. Childhood activity on progression in limb girdle muscular dystrophy 2I. J Child Neurol 2017; 32 (02) 204-209
82 Melacini P, Fanin M, Duggan DJ. , et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999; 22 (04) 473-479
83 Kirschner J, Lochmüller H. Sarcoglycanopathies. Handb Clin Neurol 2011; 101: 41-46
84 van Rijsingen IA, Arbustini E, Elliott PM. , et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 2012; 59 (05) 493-500
85 Poppe M, Bourke J, Eagle M. , et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol 2004; 56 (05) 738-741
86 Belaya K, Rodríguez Cruz PM, Liu WW. , et al. Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. Brain 2015; 138 (Pt 9): 2493-2504
87 Harris E, McEntagart M, Topf A. , et al. Clinical and neuroimaging findings in two brothers with limb girdle muscular dystrophy due to LAMA2 mutations. Neuromuscul Disord 2017; 27 (02) 170-174
88 Bögershausen N, Shahrzad N, Chong JX. , et al. Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability. Am J Hum Genet 2013; 93 (01) 181-190
89 Vissing J, Barresi R, Witting N. , et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016; 139 (Pt 8): 2154-2163
90 Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010; 20 (10) 2447-2460
91 Bushby K. Diagnosis and management of the limb girdle muscular dystrophies. Pract Neurol 2009; 9 (06) 314-323
92 Thompson R, Straub V. Limb-girdle muscular dystrophies—international collaborations for translational research. Nat Rev Neurol 2016; 12 (05) 294-309
93 Reddy HM, Hamed SA, Lek M. , et al. Homozygous nonsense mutation in SGCA is a common cause of limb-girdle muscular dystrophy in Asyut, Egypt. Muscle Nerve 2016; 54 (04) 690-695
94 Narayanaswami P, Weiss M, Selcen D. , et al; Guideline Development Subcommittee of the American Academy of Neurology; Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2014; 83 (16) 1453-1463
95 Godfrey C, Escolar D, Brockington M. , et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006; 60 (05) 603-610
96 Barthélémy F, Wein N, Krahn M, Lévy N, Bartoli M. Translational research and therapeutic perspectives in dysferlinopathies. Mol Med 2011; 17 (9–10): 875-882
97 Davis J, Samuels E, Mullins L. Nutrition considerations in Duchenne muscular dystrophy. Nutr Clin Pract 2015; 30 (04) 511-521
98 Silva MC, Magalhães TA, Meira ZM. , et al. Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol 2017; 2 (02) 190-199
99 Cheuk DK, Wong V, Wraige E, Baxter P, Cole A. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2015; (10) CD005375
100 Buckner JL, Bowden SA, Mahan JD. Optimizing bone health in Duchenne muscular dystrophy. Int J Endocrinol 2015; 2015: 928385
101 Wood CL, Straub V, Guglieri M, Bushby K, Cheetham T. Short stature and pubertal delay in Duchenne muscular dystrophy. Arch Dis Child 2016; 101 (01) 101-106